Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.53 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15823964 | 0.95 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ATGFBR1TGFBR2 | |
| SCHEMBL991856 | 0.84 | NPC1 (0.65) | SMN1; SMN2NPC1RAB9ATGFBR1ATM | |
| SCHEMBL15733342 | 0.83 | NPC1 (0.63) | SMN1; SMN2NPC1RAB9ATGFBR1ATM | |
| SCHEMBL9436258 | 0.83 | TGFBR1 (0.69) | SMN1; SMN2NPC1RAB9ATGFBR1TGFBR2 | |
| SCHEMBL4839190 | 0.79 | NPC1 (0.59) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL9293426 | 0.79 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ATGFBR1TGFBR2 | |
| SCHEMBL15823276 | 0.78 | CSNK1D (0.42) | SMN1; SMN2NPC1RAB9AALDH1A1CSNK1D | |
| SCHEMBL7343693 | 0.77 | TGFBR1 (0.65) | SMN1; SMN2TGFBR1TGFBR2CSNK1DCSNK1E | |
| SCHEMBL7378515 | 0.77 | TGFBR1 (0.65) | SMN1; SMN2TGFBR1TGFBR2CSNK1DCSNK1E | |
| SCHEMBL17767627 | 0.74 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9ATGFBR1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127426-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-05-10 | — | — | US | disclosed |
| US-9884868-B2 | TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| EP-2935271-B1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 / INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2935271-B1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 / INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9556179-B2 | Substituted imidazoles as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556179-B2 | Substituted imidazoles as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556179-B2 | Substituted imidazoles as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160257690-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
| US-20160257690-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
| US-20150344481-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-03 | — | — | US | disclosed |
| US-7320995-B2 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1720862-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1554272-B1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | LILLY CO ELI (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | EIL LILLY AND COMPANY (US) | 2005-12-08 | — | — | US | disclosed |
| WO-2005080380-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-0231622-B1 | Inhibition of the 5-lipoxygenase pathway | SMITHKLINE BEECHAM CORP (US) | 1994-08-24 | — | — | EP | disclosed |
| US-4751310-A | Inhibition of the 5-lipoxygenase pathway | SMITHKLINE BECKMAN CORPORATION (US) | 1988-06-14 | — | — | US | disclosed |
| US-4719218-A | ENZYME INHIBITORS | SMITHKLINE BECKMAN CORPORATION (US) | 1988-01-12 | — | — | US | disclosed |
| EP-0231622-A2 | Inhibition of the 5-lipoxygenase pathway | SMITHKLINE BEECHAM CORPORATION (US) | 1987-08-12 | — | — | EP | disclosed |
| CN-86108538-A | The inhibition of 5-lipoxygenase pathway | — | 1987-07-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | MAP3K8, MAPK8, MAPK1 | SMN1; SMN2 4631/4885NPC1 4504/4885RAB9A 1985/4885 |
| US-20180127426-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | SMN1; SMN2 2084/4885NPC1 2491/4885RAB9A 2258/4885 |
| US-20150344481-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | SMN1; SMN2 4413/4885NPC1 1925/4885RAB9A 2123/4885 |
| US-20160257690-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | SMN1; SMN2 2084/4885NPC1 2491/4885RAB9A 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.